Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer

LOS ANGELES, June 16, 2022 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), a Los Angeles based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of Pancreatic...

Click to view original post